A share price of Black Diamond Therapeutics Inc [BDTX] is currently trading at $2.25, up 13.07%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BDTX shares have gain 10.84% over the last week, with a monthly amount glided 40.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Black Diamond Therapeutics Inc [NASDAQ: BDTX] stock has seen the most recent analyst activity on July 31, 2024, when Raymond James initiated its Outperform rating and assigned the stock a price target of $20. On June 30, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $10 on the stock. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $11 on June 28, 2023. Wedbush upgraded its rating to a Outperform but $10 remained the price target by the analyst firm on June 27, 2023. Wedbush downgraded its rating to Neutral for this stock on March 29, 2022. In a note dated March 22, 2022, H.C. Wainwright downgraded an Neutral rating on this stock.
Black Diamond Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.20 and $6.75. Currently, Wall Street analysts expect the stock to reach $14.75 within the next 12 months. Black Diamond Therapeutics Inc [NASDAQ: BDTX] shares were valued at $2.25 at the most recent close of the market. An investor can expect a potential return of 555.56% based on the average BDTX price forecast.
Analyzing the BDTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is 0.05 and Total Capital is -0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.0700 points at the first support level, and at 1.8900 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.3400, and for the 2nd resistance point, it is at 2.4300.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Black Diamond Therapeutics Inc [NASDAQ:BDTX] is 9.24. In addition, the Quick Ratio stands at 9.24 and the Cash Ratio stands at 5.84. Considering the valuation of this stock, the price to sales ratio is 1.83, the price to book ratio is 0.90 and price to earnings (TTM) ratio is 36.47.
Transactions by insiders
Recent insider trading involved BIOTECH GROWTH N V, 10% Owner, that happened on Mar 19 ’25 when 5.78 million shares were sold. 10% Owner, Versant Venture Capital VI, L. completed a deal on Aug 28 ’24 to sell 0.22 million shares. Meanwhile, Former Employer David Epstein bought 50000.0 shares on Jul 31 ’24.
